Published in J Clin Microbiol on May 04, 2011
Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections. Clin Microbiol Rev (2016) 0.89
Optimized In Vitro Antibiotic Susceptibility Testing Method for Small-Colony Variant Staphylococcus aureus. Antimicrob Agents Chemother (2016) 0.79
The Small Colony Variant of Listeria monocytogenes Is More Tolerant to Antibiotics and Has Altered Survival in RAW 264.7 Murine Macrophages. Front Microbiol (2016) 0.75
Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA (2010) 2.75
The small colony variant (SCV) concept -- the role of staphylococcal SCVs in persistent infections. Injury (2006) 1.85
High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis (2003) 1.84
The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother (2008) 1.26
Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med (2003) 9.78
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A (2006) 8.85
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med (2011) 8.73
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 5.51
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA (2003) 4.31
Consensus statement for inert gas washout measurement using multiple- and single- breath tests. Eur Respir J (2013) 3.34
Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol Microbiol (2007) 2.87
Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA (2010) 2.75
Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med (2014) 2.63
Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax (2007) 2.60
Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa. J Bacteriol (2003) 2.41
Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest (2010) 2.29
Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med (2003) 2.26
The relationship between single-breath diffusion capacity of the lung for nitric oxide and carbon monoxide during various exercise intensities. Chest (2004) 2.23
Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. Thorax (2013) 2.20
Statewide NICU central-line-associated bloodstream infection rates decline after bundles and checklists. Pediatrics (2011) 2.15
Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol (2010) 2.11
Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatr Pulmonol (2012) 2.08
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med (2011) 2.04
Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol (2008) 2.03
Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.03
Prevalence of methicillin-sensitive and methicillin-resistant Staphylococcus aureus in pregnant women. Obstet Gynecol (2006) 2.03
Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect (2002) 2.01
Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax (2010) 1.97
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr (2008) 1.96
Statement on Exercise Testing in Cystic Fibrosis. Respiration (2015) 1.93
Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol (2004) 1.91
Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients. J Clin Microbiol (2002) 1.87
Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit Care Med (2002) 1.87
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest (2003) 1.86
Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med (2010) 1.82
Diagnostic value of nasal nitric oxide measured with non-velum closure techniques for children with primary ciliary dyskinesia. J Pediatr (2011) 1.81
Risk factors for late onset gram-negative sepsis in low birth weight infants hospitalized in the neonatal intensive care unit. Pediatr Infect Dis J (2006) 1.80
Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J Clin Invest (2006) 1.79
Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. Am J Respir Crit Care Med (2013) 1.76
Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. Nat Biotechnol (2012) 1.73
Prevalence of low bone mass and deficiencies of vitamins D and K in pediatric patients with cystic fibrosis from 3 Canadian centers. Pediatrics (2008) 1.72
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros (2008) 1.71
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med (2002) 1.70
Skeletal muscle metabolism in cystic fibrosis and primary ciliary dyskinesia. Pediatr Res (2011) 1.70
Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis (2008) 1.69
Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis. Environ Microbiol (2003) 1.68
Effect of antiseptic handwashing vs alcohol sanitizer on health care-associated infections in neonatal intensive care units. Arch Pediatr Adolesc Med (2005) 1.68
Sputum induction in routine clinical care of children with cystic fibrosis. J Pediatr (2010) 1.67
Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. Am J Respir Crit Care Med (2014) 1.66
Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros (2011) 1.65
A review of antimicrobial control strategies in hospitalized and ambulatory pediatric populations. Pediatr Infect Dis J (2007) 1.65
Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol (2014) 1.64
Disparities in access to lung transplantation for patients with cystic fibrosis by socioeconomic status. Am J Respir Crit Care Med (2012) 1.64
Underuse of effective measures to prevent and manage pediatric tuberculosis in the United States. Arch Pediatr Adolesc Med (2008) 1.62
Risk of post-lung transplant renal dysfunction in adults with cystic fibrosis. Chest (2012) 1.60
Outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit linked to artificial nails. Infect Control Hosp Epidemiol (2004) 1.59
Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One (2011) 1.58
Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest (2009) 1.57
Time for a neonatal-specific consensus definition for sepsis. Pediatr Crit Care Med (2014) 1.56
The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest (2009) 1.56
Molecular epidemiology of gram-negative bacilli from infected neonates and health care workers' hands in neonatal intensive care units. Clin Infect Dis (2004) 1.56
beta2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics (2002) 1.54
Risk factors for chronic kidney disease in adults with cystic fibrosis. Am J Respir Crit Care Med (2011) 1.53
Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis. Eur Respir J (2013) 1.53
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemp Clin Trials (2009) 1.53
Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway. PLoS Pathog (2010) 1.50
Risk factors for candidemia in critically ill infants: a matched case-control study. J Pediatr (2005) 1.49
Antibiotic use in neonatal intensive care units and adherence with Centers for Disease Control and Prevention 12 Step Campaign to Prevent Antimicrobial Resistance. Pediatr Infect Dis J (2009) 1.48
Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control (2003) 1.48
Ibuprofen modulates NF-kB activity but not IL-8 production in cystic fibrosis respiratory epithelial cells. Respiration (2009) 1.46
Evaluation and treatment of neonates with suspected late-onset sepsis: a survey of neonatologists' practices. Pediatrics (2002) 1.45
Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc (2014) 1.43
Cell phone intervention to improve adherence: cystic fibrosis care team, patient, and parent perspectives. Pediatr Pulmonol (2010) 1.41
Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis. J Clin Microbiol (2003) 1.40
Impact of staffing on bloodstream infections in the neonatal intensive care unit. Arch Pediatr Adolesc Med (2006) 1.36
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros (2009) 1.35
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol (2006) 1.34
Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. Clin Infect Dis (2013) 1.34
Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J (2011) 1.31
Epidemiology of candidemia at a Children's hospital, 2002 to 2006. Pediatr Infect Dis J (2009) 1.30
Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol (2008) 1.30
Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol (2010) 1.29
Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA (2012) 1.25
Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med (2003) 1.24
Multistate outbreak of Pseudomonas fluorescens bloodstream infection after exposure to contaminated heparinized saline flush prepared by a compounding pharmacy. Clin Infect Dis (2008) 1.23
Contribution of Burkholderia cenocepacia flagella to infectivity and inflammation. Infect Immun (2004) 1.22
Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis (2002) 1.22